NCT01028781View on ClinicalTrials.gov

Open Label of Thalidomide in Treatment of Women With Chronic Pelvic Pain Associated With Endometriosis

PHASE1TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

August 31, 2009

Study Completion Date

August 31, 2009

Conditions
Endometriosis
Interventions
DRUG

Thalidomide

Pill form, 50mgs with increasing dosage up to a maximum of 250 mg qd based on pain reports, taken once daily for 14-16 weeks with one 6 month follow-up appointment.

Trial Locations (1)

27599

UNC Chapel Hill, Chapel Hill

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

University of North Carolina, Chapel Hill

OTHER